During PD-1/PD-L1 combined with chemotherapy, the decrease of leukocytes and neutrophils may increase the risk of pneumonia during immunotherapy, and it needs to be clinically distinguished from immune-related pneumonitis. Here, PDCD1 is linked to susceptibility to pneumonia measurement.